InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
Rhea-AI Summary
InflaRx (Nasdaq: IFRX) priced an underwritten offering of 75,000,000 ordinary shares at $2.00 per share, for gross proceeds of approximately $150 million. The offering is expected to close on May 7, 2026, subject to customary closing conditions.
The company intends to use net proceeds to advance its pipeline activities and for working capital and general corporate purposes. Institutional participation includes several new and existing investors; Guggenheim Securities is lead bookrunner.
Positive
- $150 million gross proceeds from the offering
- Participation from multiple institutional investors including TCGX and Farallon
- Proceeds earmarked to advance pipeline activities and for working capital
Negative
- Issuance of 75,000,000 new shares will increase shares outstanding and dilute existing holders
- Offering priced at $2.00 could increase market share supply upon closing
News Market Reaction – IFRX
In the May 6 session, IFRX gained 26.90%, reflecting a significant positive market reaction. Argus tracked a peak move of +33.6% during that session. Our momentum scanner triggered 31 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 3.0x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Equity offering closing | Negative | +1.1% | Closed prior public offering, raising about $30M in gross proceeds. |
| Feb 13 | Offering pricing | Negative | -25.9% | Priced $30M public offering of shares and pre-funded warrants. |
| Feb 13 | Offering announcement | Negative | -25.9% | Announced commencement of underwritten public offering and pre-funded warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent equity offerings often triggered sharp negative reactions, with occasional mild strength on closing announcements.
Over the past year, InflaRx has repeatedly accessed equity markets. In February 2025, it announced and priced a public offering of ordinary shares and pre-funded warrants, followed by a closing that raised about $30 million in gross proceeds. Price reactions to the announcement and pricing headlines were around -25.93%, while the closing headline saw a modest 1.06% gain. Today’s offering pricing fits this pattern of financing-driven news, though prior reactions ranged from significant selloffs to slight strength post-closing.
Key Terms
underwritten offering financial
pre-funded warrants financial
prospectus supplement regulatory
bookrunner financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of
The Company intends to use the net proceeds from the offering to advance its pipeline activities and for working capital and general corporate purposes.
The financing included participation from new and existing investors, including TCGX, a large healthcare-dedicated fund, Farallon Capital Management, Sirenia Capital Management LP, Columbia Threadneedle Investments, Great Point Partners, LLC, ADAR1 Capital Management, Coastlands Capital, Squadron Capital Management and other large new mutual funds.
Guggenheim Securities is acting as lead bookrunner for the offering. Oppenheimer & Co. and LifeSci Capital are also acting as bookrunners for the offering. Raymond James and Needham & Company are acting as co-lead managers for the offering. H.C. Wainwright & Co. and Lucid Capital Markets are acting as co-managers for the offering.
A shelf registration statement relating to the ordinary shares and pre-funded warrants being sold in this offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on July 11, 2023. The offering will be made only by means of a prospectus and prospectus supplement. The final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. When available, copies of the prospectus supplement and accompanying prospectus related to the offering may be obtained by contacting Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of AAV and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
